News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xencor, Inc. - Common Stock
(NQ:
XNCR
)
14.92
-0.39 (-2.55%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xencor, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
December 09, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor to Participate at Upcoming Investor Conferences
November 10, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Third Quarter 2025 Financial Results
November 05, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
October 24, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
October 21, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor to Participate at Upcoming Investor Conferences
August 27, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Second Quarter 2025 Financial Results
August 06, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
July 31, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Reports First Quarter 2025 Financial Results
May 07, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
April 29, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Appoints Todd Simpson to Board of Directors
March 13, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
From
Xencor, Inc.
Via
Business Wire
Xencor to Participate at Upcoming Investor Conferences
November 26, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
November 04, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
October 10, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Upcoming Change to Board of Directors
October 04, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 12, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
September 11, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Proposed Public Offering of Common Stock
September 10, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
September 09, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
September 06, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Second Quarter 2024 Financial Results
August 05, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
June 13, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports First Quarter 2024 Financial Results
May 09, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Appoints Bart Cornelissen as Chief Financial Officer
April 09, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
February 28, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
February 20, 2024
From
Xencor, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
